CTLA4 and metastatic melanoma: Despite advancements in treatments such as immune checkpoint inhibitors targeting PD-1 or CTLA-4, and therapies for BRAF/MEK mutations, the prognosis for metastatic melanoma remains poor, with a five-year survival rate of just 32% (2, 3).